A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson’s disease
Part of the
Journal of Neural Transmission
book series (NEURAL SUPPL, volume 27)
At the first stage of a pilot study involving 14 parkinsonians with motor fluctuations, treatment with standard Madopar was substituted by a sustained-release form, Madopar HBS, which attenuated fluctuations in patients with end-of-dose impairment, but achieved only moderate improvement in patients with on-off phenomena.
In a second phase of the trial, 4 parkinsonians exhibiting the most severe fluctuations of mobility and the poorest response to Madopar HBS (Hydrodynamically Balanced System) were selected for treatment with a combined regimen utilizing subcutaneous lisuride infusions as the additional component. The sequence of the trial was as follows:
standard Madopar combined with lisuride infusions and
Madopar HBS combined with lisuride infusions.
Steady improvement was observed along the lines of this schedule, but the best results were obtained when Madopar HBS was combined with lisuride infusions. Subsequently motor fluctuations were less marked or disappeared, early-morning Parkinson symptoms decreased and dystonia was not recorded any longer. Even better results could be accomplished in an extended trial attempting to establish the best dosage ratio of the combination, possibly admitting increased dosage.
The tolerance of the combined regimen was excellent, except in one patient who transiently exhibited delusions and postural hypotension. The combination of sustained-release Madopar and continuous infusions of the dopaminergic agonist lisuride seems to prove a more physiological and effective regimen for the treatment of severe motor fluctuations.
KeywordsPostural Hypotension Motor Fluctuation Subcutaneous Infusion Combine Regimen Good Therapeutic Result
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Chouza C, Romero S, Gomensoro JB (1975) “Long-term syndrome” en el tratamiento del parkinsonismo con L-dopa. Acta Neurol Latinoam 21: 108–125Google Scholar
Chouza C, Romero S, de Medina O, Aljanati R, Scaramelli A, Caamano JL, Gonzalez Panizza V (1987) Substitution of standard Madopar for Madopar HBS in parkinsonians with fluctuations. Eur Neurol 27 [Suppl 1]: 59–67Google Scholar
Fahn S (1974) On-off phenomenon with levodopa therapy in parkinsonism. Neurology 24: 431–441PubMedCrossRefGoogle Scholar
Juncos J, Serrati C, Fabbrini G, Chase TN (1985) Fluctuating levodopa concentrations and Parkinson’s disease. Lancet 1: 440CrossRefGoogle Scholar
Obeso JA, Luquin MR, Martinez-Lage JM (1986) Intravenous lisuride corrects oscillations of motor performance in Parkinson’s disease. Ann Neurol 19: 31–35PubMedCrossRefGoogle Scholar
Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1: 467–470PubMedCrossRefGoogle Scholar
Quinn N, Parkes P, Marsden D (1984) Control of on-off phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136PubMedCrossRefGoogle Scholar
Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144–1148PubMedCrossRefGoogle Scholar
Tolosa ES, Martin WE, Cohen HP, Jacobson RL (1975) Patterns of clinical response and plasma dopa levels in Parkinson’s disease. Neurology 25: 177–184PubMedCrossRefGoogle Scholar